Genomate Health

Genomate Health Genomate Health is a digital health company that develops computational solutions for personalized medicine.

When a child is diagnosed with cancer, everything changes. For the family. For the care team. And for those working behi...
02/16/2026

When a child is diagnosed with cancer, everything changes. For the family. For the care team. And for those working behind the scenes to help find the best possible path forward.

At Genomate Health, we think about the young patients whose molecular profiles we review. A name. An age. A life just beginning. A child whose doctors are searching for clarity in the face of complexity.

That responsibility shapes how we work. It drives our rigor. It demands precision. It reminds us that behind every dataset is a future that deserves protecting.

Today, we stand with children and families navigating the unimaginable. And we recommit to doing our part, so that every child facing cancer has the strongest, most informed care possible behind them.

February 11 is the International Day of Women and Girls in Science, a reminder that the future of science depends on who...
02/11/2026

February 11 is the International Day of Women and Girls in Science, a reminder that the future of science depends on who gets to shape it.

At Genomate Health, more than half of our team is women.
They lead research that untangles molecular complexity.
They design tools that help oncologists act with clarity.
They manage systems, build technology, and shape our strategy.
Their work isn’t just essential to our mission, it defines how we deliver on it.

We believe that real innovation in precision oncology requires many perspectives at the table. Equity isn’t a tagline. It’s what makes science stronger, more honest, and more useful to the people it serves.

To our colleagues, and to all women across STEM: thank you 💚

Learn more about the women working at Genomate Health: https://www.genomate.health/news-article/celebrating-women-in-science

What if molecular complexity wasn’t a barrier, but a roadmap?At the upcoming AAAS Annual Meeting, our Founder and CSO, I...
02/06/2026

What if molecular complexity wasn’t a barrier, but a roadmap?

At the upcoming AAAS Annual Meeting, our Founder and CSO, Istvan Petak MD, PhD, will explore how computational reasoning can help oncologists and researchers translate genomic data into therapy decisions that actually work.

Why does it matter?
Because most tumors don’t follow textbook rules. And matching a patient to the right targeted therapy or trial often means navigating dozens of biomarkers, resistance pathways, and conflicting evidence.

If you're working to bring more precision, consistency, or equity to cancer care, this is a conversation you don't want to miss: https://aaas.confex.com/aaas/2026/meetingapp.cgi/Paper/35453

Cancer doesn’t play fair. But it can be outplayed.This , we’re reminded that cancer adapts. It learns. It finds workaro...
02/03/2026

Cancer doesn’t play fair. But it can be outplayed.

This , we’re reminded that cancer adapts. It learns. It finds workarounds.

That’s why we need smarter tools, not just to keep up, but to think ahead.

At Genomate Health, we use computational reasoning to help oncologists see the full board. Our platform analyzes complex tumor profiles and highlights evidence-based treatments, so clinicians can make confident, strategic moves, even in the toughest cases.

Because beating cancer takes more than new therapies.
It takes clarity, foresight, and the ability to plan three steps ahead.

We’re proud to see our story featured in Telex.hu highlighting how Hungarian innovation is shaping the future of cancer ...
01/28/2026

We’re proud to see our story featured in Telex.hu highlighting how Hungarian innovation is shaping the future of cancer care on the global stage: https://telex.hu/g7/adat/2026/01/28/oncompass-petak-istvan-genomate-budapest-boston-rakdiagnosztika

Both Genomate Health and Oncompass Medicine started with a bold vision: to understand each tumor at the molecular level and help clinicians make more informed, personalized treatment decisions. Today, that vision continues as a united, international company serving patients and clinicians across Europe and the US.

How can we turn complex tumor profiles into clear, evidence-based treatment decisions?On January 30, Genomate Health Fou...
01/28/2026

How can we turn complex tumor profiles into clear, evidence-based treatment decisions?

On January 30, Genomate Health Founder and CSO Istvan Petak MD, PhD will speak at the Center for Cancer Research Impromptu Seminar Series, hosted by Gergely Szakacs, to explore this question and more.

Join us to learn how structured, algorithmic tools are helping improve consistency, confidence, and outcomes in precision oncology.

Sign up here: https://lnkd.in/dQmsreTp

Cervical cancer is one of the most preventable and treatable cancers, if caught early. Screening, HPV vaccination, and t...
01/22/2026

Cervical cancer is one of the most preventable and treatable cancers, if caught early. Screening, HPV vaccination, and timely care have changed the outlook for millions. But progress isn’t equal everywhere.

Too many people are still diagnosed late. Too many face barriers to testing or lack access to care tailored to the biology of their cancer. At Genomate Health, we focus on the moments after diagnosis, helping oncologists make evidence-based treatment decisions, especially when standard options fall short.

This month, we stand with the clinicians, researchers, and advocates working to ensure everyone has access to the tools to eliminate cervical cancer.

Today marks a major milestone for Genomate Health. We are thrilled to announce we’ve acquired Oncompass Medicine, a Euro...
01/14/2026

Today marks a major milestone for Genomate Health. We are thrilled to announce we’ve acquired Oncompass Medicine, a European pioneer in precision oncology with more than two decades of clinical and diagnostic leadership.

This acquisition:
↘ Establishes Genomate Health’s European operational and diagnostics base
↘ Expands our clinical, laboratory, and R&D capabilities in Budapest
↘ Integrates deep molecular diagnostics expertise with computational reasoning
↘ Accelerates global deployment of clinically validated precision oncology solutions

Oncompass Medicine will continue operating in Hungary as Oncompass Medicine, a Genomate Health company: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/genomate-health-expands-global-footprint-with-acquisition-of-oncompas-1113068

Together, we are building a unified precision oncology platform that transforms complex molecular data into clinically relevant treatment decisions, at scale.

By the end of 2025, Genomate Health had crossed a critical threshold. Genomate® had been scientifically validated, deplo...
01/13/2026

By the end of 2025, Genomate Health had crossed a critical threshold. Genomate® had been scientifically validated, deployed in early clinical use, and engaged with regulators as a new category of precision oncology software.

As we move into 2026, the focus shifts from proving what is possible to scaling what works: expanding clinical adoption, advancing regulatory pathways, and continuing to build evidence that supports equitable access to precision oncology.

Read all about our 2025 here: https://www.genomate.health/news-article/genomate-health-2025-in-review

As we close out the year, we pause to appreciate the progress made in cancer care and the people who make that progress ...
12/24/2025

As we close out the year, we pause to appreciate the progress made in cancer care and the people who make that progress real, every day.

Wishing you a joyful holiday season and a healthy, successful year ahead 💚

- The Genomate Health team

Our CEO Nabil Hafez will be in San Francisco during JPM Healthcare Week 2026, and he’s looking forward to connecting wit...
12/23/2025

Our CEO Nabil Hafez will be in San Francisco during JPM Healthcare Week 2026, and he’s looking forward to connecting with peers, partners, and investors along the way.

At Genomate Health, we’re focused on making precision oncology more consistent, reproducible, and actionable using computational reasoning. If you’re working on clinical decision support, biomarker-driven therapy selection, or thinking about how to scale precision medicine beyond academic centers, we’d love to work together.

Learn more and book some time to chat here: https://www.genomate.health/event/genomate-health-at-jpm-2026

A new real-world study in Cancer Medicine (2025) shows both the promise (and the limits) of precision oncology.Molecular...
12/19/2025

A new real-world study in Cancer Medicine (2025) shows both the promise (and the limits) of precision oncology.

Molecular Tumor Boards recommended biomarker-matched therapies for 59% of profiled patients, yet only 17% ultimately received them. When patients did gain access, the impact was meaningful: 41% achieved longer progression-free survival compared with their previous line of treatment.

The message is clear. Biomarker-guided care works, but access doesn’t scale.

This is the gap Genomate addresses. By translating complex molecular data into actionable, computational reasoning–driven treatment insights, Genomate extends molecular decision support beyond academic centers, bringing precision oncology to every patient, everywhere.

Read the study: https://onlinelibrary.wiley.com/doi/10.1002/cam4.71119

Address

Cambridge, MA

Website

Alerts

Be the first to know and let us send you an email when Genomate Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Genomate Health:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category